share_log

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q: Q3 2024 Earnings Report

Insmed | 10-Q：2024财年三季报
美股SEC公告 ·  2024/10/31 07:05

Moomoo AI 已提取核心信息

Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed reported strong financial results for Q3 2024, with total revenue increasing 18.2% to $93.4 million compared to $79.1 million in Q3 2023. The growth was driven by ARIKAYCE sales expansion across all regions, with US revenue up 12.9% to $66.9 million, Japan revenue up 30.9% to $21.0 million, and Europe revenue up 45.3% to $5.6 million.Research and development expenses increased to $150.8 million from $109.1 million in Q3 2023, primarily due to higher manufacturing costs and increased headcount. SG&A expenses rose to $118.9 million from $90.6 million, driven by higher personnel costs and commercial readiness activities for brensocatib. The company reported a net loss of $220.5 million compared to $158.9 million in Q3 2023.The company maintained a strong financial position with $461.5 million in cash and cash equivalents plus $1.0 billion in marketable securities as of September 30, 2024. Insmed remains on track to file an NDA for brensocatib in bronchiectasis in Q4 2024 following positive Phase 3 ASPEN trial results. The company also closed screening for the ENCORE study of ARIKAYCE, with topline data expected in Q1 2026.
Insmed在2024年第三季度报告了强劲的财务业绩，总营业收入同比增长18.2%，达到9340万美金，相较于2023年第三季度的7910万美金。增长主要受到ARIKAYCE在所有地区销售扩展的推动，美国营业收入增长12.9%，达到6690万美金，日本营业收入增长30.9%，达到2100万美金，欧洲营业收入增长45.3%，达到560万美金。研究和开发费用从2023年第三季度的10910万美金增加到15080万美金，主要是由于制造业-半导体成本的增加和员工人数的增加。SG&A费用从9060万美金上升至11890万美金，主要由于人员成本和brensocatib的商业准备活动增加。公司报告净亏损为2...展开全部
Insmed在2024年第三季度报告了强劲的财务业绩，总营业收入同比增长18.2%，达到9340万美金，相较于2023年第三季度的7910万美金。增长主要受到ARIKAYCE在所有地区销售扩展的推动，美国营业收入增长12.9%，达到6690万美金，日本营业收入增长30.9%，达到2100万美金，欧洲营业收入增长45.3%，达到560万美金。研究和开发费用从2023年第三季度的10910万美金增加到15080万美金，主要是由于制造业-半导体成本的增加和员工人数的增加。SG&A费用从9060万美金上升至11890万美金，主要由于人员成本和brensocatib的商业准备活动增加。公司报告净亏损为22050万美金，相较于2023年第三季度的15890万美金。截至2024年9月30日，公司保持了强大的财务状况，现金及现金等价物为46150万美金，加上10亿美金的可交易证券。Insmed仍按计划在2024年第四季度提交brensocatib在支气管扩张症的NDA，因其积极的ASPEN三期试验结果。公司还关闭了对ARIKAYCE的ENCORE研究的筛选，预计将在2026年第一季度公布顶线数据。

该公告为独立文件：

独立文件1  查看翻译

独立文件2  查看翻译

独立文件3  查看翻译

独立文件4  查看翻译

独立文件5  查看翻译

声明：本内容仅用作提供资讯及教育之目的，不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    相关股票 相关股票
    代码 迷你走势 最新价
    Portage Biotech
    PRTG
    -- 9.600
    莱斯康制药
    LXRX
    -- 0.571
    DBV Technologies
    DBVT
    -- 6.200
    NeOnc Technologies
    NTHI
    -- 16.550
    Alumis
    ALMS
    -- 5.640
    解锁完整榜单
    重估中国资产
    继中国开创性的DeepSeek技术推出之后， 华尔街大行重估对中国市场的投资前景。
    热门讨论
    中概股财报季火热：惊喜盈利能否延续涨势？
    1. 哪些行业可能成为本轮中概股财报季的市场焦点？ 2. 在政府强调科技创新和可持续发展的背景下，你认为哪些行业具有最大的增长潜力？ 展开
    中国两会：会议前后股票价格走势的主要要点